About lab
One published Lab
Build with this Lab. Run it anywhere.
Use the same immutable release locally or through managed cloud execution, with its exact version and provenance preserved.
Preparing exact examples…
PURPOSE: This tumor response pharmacodynamic model aims to describe primary lesion shrinkage in non-small cell lung cancer over time and determine if concentration-based exposure metrics for gemcitabi. It can be used to explore tumor-related dynamics and compare treatment-response behavior across conditions.
Manifest
{
"io": {
"inputs": [
{
"name": "dose_int2_source_parameter",
"label": "Dose Int2 source parameter",
"units": "native SBML value",
"default": -2,
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.dose_int2_source_parameter",
"description": "Dose Int2 source parameter. Maps to bundled SBML parameter `Dose_Int2`."
},
{
"name": "dose_int1_source_parameter",
"label": "Dose Int1 source parameter",
"units": "native SBML value",
"default": 0,
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.dose_int1_source_parameter",
"description": "Dose Int1 source parameter. Maps to bundled SBML parameter `Dose_Int1`."
},
{
"name": "dose_source_parameter",
"label": "Dose source parameter",
"units": "native SBML value",
"default": 5203.84,
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.dose_source_parameter",
"description": "Dose source parameter. Maps to bundled SBML parameter `Dose`."
},
{
"name": "initial_tumor_size",
"label": "TumorSize",
"units": "native SBML value",
"default": 6.66,
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.initial_tumor_size",
"description": "Initial TumorSize. Sets the initial value of bundled SBML symbol `TumorSize`."
}
],
"outputs": [
{
"name": "tumor_size",
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.tumor_size",
"description": "TumorSize observable. Maps to SBML symbol `TumorSize`."
},
{
"name": "ce",
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.ce",
"description": "Ce observable. Maps to SBML symbol `Ce`."
},
{
"name": "state",
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.state",
"description": "Full raw SBML observable record for reproducibility and downstream visualisation."
},
{
"name": "summary",
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.summary",
"description": "Change and peak summary across the simulated SBML observables."
},
{
"name": "species_labels",
"maps_to": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.species_labels",
"description": "Mapping from selected raw SBML observable symbols to display labels."
}
]
},
"tags": [
"biomodels_ebi",
"chemotherapy",
"curated",
"drug-response",
"faithful",
"oncology",
"pharmacology",
"physiology",
"sbml",
"systemsbiology",
"tumor-growth"
],
"title": "Tham2008 - PDmodel, Tumour shrinkage by gemcitabine and carboplatin Lab",
"models": [
{
"path": "models/core",
"alias": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model"
},
{
"path": "models/visualisation",
"alias": "visualisation"
}
],
"wiring": [
{
"to": [
"visualisation.oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model_state"
],
"from": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.state"
},
{
"to": [
"visualisation.oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model_summary"
],
"from": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.summary"
},
{
"to": [
"visualisation.oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model_species_labels"
],
"from": "oncology_sbml_tham2008_pdmodel_tumour_shrinkage_by_gemcitabine_biomd0000000234_model.species_labels"
}
],
"package": "tham2008-pdmodel-tumour-shrinkage-by-gemcitabine-and-carboplatin",
"runtime": {
"duration": 10,
"initial_inputs": {},
"communication_step": 1
},
"version": "1.0.0",
"description": "PURPOSE: This tumor response pharmacodynamic model aims to describe primary lesion shrinkage in non-small cell lung cancer over time and determine if concentration-based exposure metrics for gemcitabi. It can be used to explore tumor-related dynamics and compare treatment-response behavior across conditions.",
"schema_version": "2.0"
}Runtime
Duration10
Comms Step1
Runs
Total0
Completed0
Failed0
Metadata
Packagetham2008-pdmodel-tumour-shrinkage-by-gemcitabine-and-carboplatin
Created2026-05-16
Updated2026-06-13
biomodels_ebichemotherapycurateddrug-responsefaithfuloncologypharmacologyphysiologysbmlsystemsbiologytumor-growthvisualisationother